Summary of the fourth quarter (2022-04-01 - 2022-06-30)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,3 (-2,1)
-
Earnings per share*
SEK -0.06 (-0.11)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Summary of the financial year (2021-07-01 - 2022-06-30)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -4,9 (-5,3)
-
Earnings per share*
SEK -0.25 (-0.31) - Cash and cash equivalents at the end of the period amounted to MSEK 25,2 (35,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,790,364.Amounts in brackets refer to the corresponding period last year.
CEO's comment
The company's phase 1 study regarding OsteoDex's treatment of multiple myeloma is underway and patient recruitment is ongoing.
The principal investigator (PI) is Dr. Katarina Uttervall, MD, PhD,
Study material, GMP manufactured OsteoDex, is produced by Biovian OY,
Anders R Holmberg
Contact
This information is such information that
https://news.cision.com/dextech/r/dextech-medical-ab--year-end-report-july-1--2021---june-30--2022,c3826342
https://mb.cision.com/Main/11652/3826342/2262193.pdf
(c) 2023 Cision. All rights reserved., source